Abstract
2094P A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant and olanzapine for highly emetogenic chemotherapy in breast cancer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have